"GLP-1 Diabetes Drug Slows Parkinson's Progression in Small Trial"
TL;DR Summary
A small mid-stage trial has shown that the diabetes drug lixisenatide, similar to Ozempic, helped slow the progression of motor disability in patients with early-stage Parkinson's disease. The drug, made by Sanofi, demonstrated potential in mitigating symptoms such as tremors and stiffness, but was also associated with an increased risk of gastrointestinal side effects. Larger and longer studies are needed to fully determine the efficacy and safety of this treatment for Parkinson's disease.
Topics:health#diabetes-drug#health-medical-research#lixisenatide#motor-disability#parkinsons-disease#sanofi
- Diabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial CNBC
- An Ozempic Relative Slowed Parkinson's Disease in a Small Study The New York Times
- Diabetes drug seems to slow progress of Parkinson’s in French-backed trial MarketWatch
- GLP-1 drug may help with Parkinson's disease, study reports STAT
- Diabetes drug may slow progression of Parkinson’s, say researchers The Guardian
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
86%
524 → 73 words
Want the full story? Read the original article
Read on CNBC